Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.
Surv Ophthalmol. 2021 Jul-Aug;66(4):612-622. doi: 10.1016/j.survophthal.2020.11.005. Epub 2021 Jan 29.
Meibomian gland dysfunction (MGD) is a major cause of dry eye, affecting millions worldwide. Intraductal meibomian gland probing (MGP) aims to open obstructed meibomian glands using a small probe to promote meibum secretion. MGP has received increasing interest since 2010, and we critically evaluated the literature on the efficacy and safety of MGP. Despite positive results of MGP on dry eye symptoms in early single-group studies, MGP was not shown to consistently outperform controls in later controlled trials. Furthermore, MGP alone did not show improvement beyond placebo in the only placebo-controlled RCT conducted. Overall, the procedure appears safe. Self-limited intraoperative bleeding was frequent, but no major complications were reported. In conclusion, MGP has not yet been shown to be an effective treatment for MGD. Larger placebo-controlled trials need to be conducted to establish the potential effect of this novel treatment modality.
睑板腺功能障碍（MGD）是干眼症的主要原因，影响着全球数百万人。导管内睑板腺探查（MGP）旨在使用小探针打开阻塞的睑板腺，以促进睑脂分泌。自 2010 年以来，MGP 受到了越来越多的关注，我们对 MGP 的疗效和安全性的文献进行了批判性评估。尽管早期的单组研究显示 MGP 对干眼症症状有积极的结果，但在后来的对照试验中，MGP 并不总是优于对照组。此外，在唯一一项进行的安慰剂对照 RCT 中，MGP 单独治疗并未显示出优于安慰剂的改善。总的来说，该手术似乎是安全的。术中自限性出血较为常见，但未报告重大并发症。总之，MGP 尚未被证明是治疗 MGD 的有效方法。需要进行更大规模的安慰剂对照试验来确定这种新治疗方法的潜在效果。
